Celera to Webcast Presentation as Part of the UBS West Coast Bus Tour on March 24, 2009
FOR IMMEDIATE RELEASE
Alameda, CA - March 23, 2009
Celera (NASDAQ:CRA) announced today that it will webcast its presentation to investors as part of the UBS West Coast Life Sciences Bus Tour on Tuesday, March 24, 2009, at 6:45 p.m. PT, when Kathy Ordo˝ez, Chief Executive Officer of Celera, will provide an overview of the business.
Interested parties may access the live webcasts and replay by visiting the Media and Investors section of the Celera website at www.celera.com. It is suggested that participants access the webcast 15 minutes before the start of the live broadcast. The webcast replay will be archived on the Presentations page of the Media and Investors section of website.
Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.
Copyrightę 2009. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U.S. and/or certain other countries.
David Speechly, Ph.D.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.